Cyanotech (CYAN) Q1 2025 earnings summary

Executive summary

• Net sales for Q1 FY2025 increased 15% year-over-year to $5.9 million, driven by higher astaxanthin sales in both bulk and packaged markets.

• Launched Hawaiian Spirulina gummies in May 2024 to expand product offerings.

• Gross profit margin declined to 25% from 29.8% due to higher production costs from lower volumes.

• Operating loss improved to $1 million from $1.2 million year-over-year; net loss narrowed to $1.2 million (17 cents per diluted share) from $1.4 million (22 cents per diluted share).

• Management remains positive about future brand prospects and consumer demand for sustainable, high-quality supplements.

Financial highlights

• Net sales: $5.9 million, up from $5.1 million in Q1 FY2024.

• Gross profit: $1.5 million (25% margin), down from $1.5 million (29.8% margin) year-over-year.

• Operating loss: $1 million, improved from $1.2 million loss in prior year.

• Net loss: $1.2 million, or $0.17 per share, compared to $1.4 million, or $0.22 per share, last year.

• Cash stood at $720,000 and working capital at $207,000 as of quarter end.

Outlook and guidance

• Focus is on meeting changing demand with a managed increase in supply and stabilizing production.

• Preliminary financing secured to support anticipated market demand.

• Emphasis on higher-margin consumer products and process improvements to stabilize costs.

• Management expects continued sales variability and is monitoring cash resources closely.

• Positive outlook for brand growth and consumer interest in sustainable supplements.